Comparative analysis of levosimendan and dobutamine in treatment of patients with dilated cardiomyopathy and refractory end-stage heart failure
- VernacularTitle:左西孟旦与多巴酚丁胺治疗扩张型心肌病并顽固性终末期心衰的对比分析
- Author:
Yanfeng ZHANG
1
;
Qicai LI
;
Yong ZHANG
Author Information
1. 广东省高州市人民医院心内科三区
- Keywords:
Levosimendan;
Dobutamine;
Dilated cardiomyopathy combined with refractory end -stage heart failure;
Cardiac function
- From:
China Modern Doctor
2018;56(14):34-36,40
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of levosimendan and dobutamine in the treatment of dilated cardiomyopathy combined with refractory end-stage heart failure. Methods A total of 90 patients with dilated cardiomyopathy and refractory end-stage heart failure in our hospital from February 2016 to February 2017 were enrolled and grouped according to digital table method. The control group received conventional anti-heart failure treatment and dobutamine treatment. The observation group received conventional anti -heart failure treatment and levosimendan treatment. The treatment effects of dilated cardiomyopathy and refractory end-stage heart failure, the symptom improvement time, heart failure correction time, left ventricular ejection fraction, left ventricular end diastolic diameter, brain natriuretic peptide, cardiac index before and after intervention and drug side effects rate between two groups were compared. Results The treatment effect of dilated cardiomyopathy and refractory end -stage heart failure was higher in the observation group than that in the control group(P＜0. 05). The improvement time of symptoms and the correction time of heart failure in the observation group were shorter than those in the control group(P＜0. 05). The ventricular ejection fraction, left ventricular end diastolic diameter, brain natriuretic peptide, and cardiac index in two groups were similar (P＞0. 05). After the intervention, the left ventricular ejection fraction, left ventricular end diastolic diameter, brain natriuretic peptide, and cardiac index in the observation group were superior to those of the control group(P＜0. 05). There was no significant difference in drug side effects between the two groups, both of which were mild(P＞0. 05). Conclusion Levosi-mendan has a better effect in patients with dilated cardiomyopathy and refractory end-stage heart failure than dobu- tamine does. Levosimendan can improve heart function and correct heart failure more quickly, with high drug safety, and is worth promoting.
